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Summary. Inflammation and infection are common pathogenic mechanisms involved in many otorhinolaryn-
gological (ORL) chronic diseases. Broncalt® is a class II Medical Device containing: thermal water (Mede-
sano, PR, Italy), hyaluronic acid, and grapefruit seed extract. It could exert a safe and effective anti-inflam-
matory, washing, and antimicrobial activity by virtue of these components. Therefore, the aim of the current 
survey, conducted in clinical practice of 84 Italian ORL centers, was to evaluate its safety and efficacy in the 
treatment of patients with chronic upper airways disease. The 1,817 (958 males, mean age 49 years) patients 
were evaluated at baseline (T0) and after one (T1) and two (T2) weeks of treatment, they were treated or 
not treated with Broncalt®. Signs and symptoms severity were measured by visual analogue scale. Broncalt® 
significantly, quickly, and safely diminished the clinical features in all sub-groups (p<0.001 for all). In conclu-
sion, Broncalt® is a class II Medical Device able to exert a safe, quick, and effective activity in patients with 
chronic ORL disorders. (www.actabiomedica.it)
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O r i g i n a l  a r t i c l e
Introduction
Chronic otorhinolaryngological (ORL) airways 
disorders are frequent in clinical practice. Chronic res-
piratory ORL illness include chronic rhinosinusitis, 
chronic rhinopharyngitis, chronic pharyngitis, chronic 
tonsillitis, and chronic laryngitis. 
Chronic progression of an upper acute airways 
disease usually depends on worsening pathogenic 
factors, including host immune defect, virulence of 
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pathogens, autoinflammatory/autoimmune disorders, 
climate and environmental effects, concomitant phar-
macological treatment, metabolic disease, etc (1-3). 
Therefore, the management of chronic upper airways 
disease is more complex than in acute ones and re-
quires a careful work-up. 
The treatment of chronic airways diseases is tar-
geted to fight both infection and inflammation usually 
using antibiotics and anti-inflammatory medications. 
However, pharmacological medications may have 
contraindications and may implicate adverse events. 
Therefore, the option of complementary medicine is 
up-to-date in clinical practice.
Broncalt® is a new class II medical device con-
taining salso-bromo-iodine thermal water (spring of 
Medesano, PR, Italy) 8%, hyaluronic acid (HA) 0.1%, 
and grapefruit seed extract 0.35%.
Recently, it has been reported that Broncalt® was 
effective in the treatment of postnasal drip-related 
cough in children with upper respiratory tract infec-
tions (4).
On the basis of this background, an Italian survey 
explored the pragmatic approach of a group of otolar-
yngologists in the management of chronic upper-air-
ways disorders in clinical practice. Therefore, the aim 
of the current survey was to evaluate the efficacy and 
safety of Broncalt® in outpatients with chronic ORL 
diseases.
Materials and Methods
The current survey was conducted in 84 Italian 
ORL centers, distributed in the whole Italy, so assur-
ing a wide and complete national coverage. Otolaryn-
gologists were asked to recruit all consecutive patients 
visited because of chronic ORL disease.
Patients were consecutively recruited during the 
specialist visit. The inclusion criteria were: to have a 
diagnosis of chronic respiratory ORL disease, both 
genders, and adulthood. Exclusion criteria were to 
have comorbidities and concomitant medications able 
to interfere the evaluation of outcomes. As this survey 
was based on a real-world practice, the doctors had the 
complete liberty of choosing the preferred medications 
on the basis of the best practice. Actually, patients were 
subdivided in 2 sub-groups: i) patients treated with 
standard therapy plus Broncalt® (active group), and ii) 
patients treated with standard therapy alone (control 
group).
Patients were suffering from acute illness, includ-
ing chronic rhinosinusitis, chronic rhinopharyngitis, 
chronic pharyngitis, chronic tonsillitis and chronic 
laryngitis.
All patients signed an informed consent. All the 
procedures were conducted in a real-world setting.
The treatment course lasted 2 weeks. The medi-
cal device Broncalt® (Aurora Biofarma, Milan, Italy) 
was taken following the specific indications, such as 
two tablets/daily. Patients were visited at baseline (T0), 
after 1-week treatment (T1), and after 2-week treat-
ment (T2).
Clinical examination and fiber-endoscopy were 
evaluated in all patients at all visits. 
All clinical data were inserted in an internet-plat-
form that guaranteed the patients’ anonymity and the 
findings’ recording accuracy. 
The following clinical parameters were evaluatat-
ed: nasal obstruction, mucosal edema, hyperemia, ear-
ache, swelling, sore throat, dysphagia, dysphonia, and 
cough. These issues were considered both as the quote 
of patients having them and their perceived severity. 
Symptom severity was assessed by a visual analogue 
scale (VAS). VAS is a psychometric test widely used to 
measure the patient’s perception of symptom severity, 
emotions, pain, etc. Currently, VAS is a reliable and val-
id tool to assess the perception of symptoms and signs 
(14). The VAS consisted of one ruler asking for signs 
and symptoms severity perception. In this study, the 
VAS was a 10-cm horizontal line on which 0 implied 
the absence of sing or symptom, while 10 corresponded 
to maximal severity. VAS is considered a routine and 
validated parameter to assess disease severity in clinical 
practice and inflammatory markers are closely related 
with nasal obstruction perception (5). 
In addition, the symptom disappearance duration 
was also considered, such as 3 period were established 
for symptom receding: by 3 days, between 4-7 days, 
and beyond 7 days.
Doctors also evaluated: the effectiveness (scored 
as very effective, effective, scarcely effective, and in-
effective), the tolerability (scored as very good, quite 
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good, poorly good, no good), and the compliance (very 
good, good, scarcely good, and no good).
Safety was measured by reporting the occurrence 
of adverse events.
The paired T-test was used. Statistical significance 
was set at p <0.05. Data are expressed as medians and 
1th and 3rd quartiles. The analysis was performed using 
STATA, College Station, Texas, USA. 
Results
Globally, 1,817 (958 males, mean age 49 years) 
patients were visited and completed the treatment 
course. 
The demographic characteristics and type of 
chronic respiratory disease are reported in Table 1.
In particular, the two subgroups were similar 
concerning the gender, but the age was higher in pa-
tients not-treated with Broncalt. The distribution of 
chronic respiratory diseases was significantly different 
about some types, i.e. patients not-treated with Bron-
calt had more frequently recurrent otitis an chronic 
tonsillitis, whereas Broncalt-treated patients suffered 
more commonly from chronic pharyngitis. Subgroup 
treated with Broncalt took significantly less antibiotics 
and anti-inflammatory drugs than the other subgroup; 
interestingly Broncalt-treated subgroups did not take 
any medication more frequently (72.8% versus 3%).
Considering the frequency of patients without 
symptoms or signs after the treatment, Broncalt treat-
ment induced higher percentages of symptomless pa-
tients for nasal obstruction, rhinorrhea, post nasal drip, 
and hyperemia (Table 2). 
Considering the severity of symptoms, patients 
treated with Broncalt showed less severe facial pain, 
earache, and sore throat than not treated patients (Fig-
ure 1).
The percentages of patients treated with or with-
out Broncalt with global symptom disappearance 
Table 1. Demographic and clinical characteristics of patients, treated with or without Borncalt
 Broncalt No Broncalt p-value
 N=1553 N=264
Characteristic
Male gender, n (%) 826 53.2% 132 50.0% 0.338
Mean age, (SD) 48.2 21.5 54.1 19.8 <0.001
Chronic disease     
Recurrent Otitis, n(%) 260  16.7% 64 24.2% 0.003
Chronic Tonsillitis, n(%) 56 3.6% 25 9.5% <0.001
Chronic Laryngitis, n(%) 244 15.7% 39 14.8% 0.697
Chronic Rhinosinusitis, n(%) 6 0.4% 1 0.4% 0.985
Chronic Rhinopharyngitis, n(%) 408 26.3% 32 12.1% <0.001
Chronic Pharyngitis, n(%) 234 15.1% 28 10.6% 0.056
Dysphonia, n(%) 165 10.6% 26 9.9% 0.704
Concomitant treatments 
Antibiotics 65 4.2% 44 16.7% 
     Cefalosporins 44 2.8% 26 9.8% 
     Chinolones 8 0.5% 7 2.7% 
     Macrolides 4 0.3% 8 3.0% 
     Other 9 0.6% 3 1.1% 
Anti-inflammatory drugs 308 19.8% 130 49.2% 
     Antipyretics 3 0.2% 3 1.1% 
     Corticosteroids 248 16.0% 92 34.8% 
     FANS 20 1.3% 20 7.6% 
    Other 37 2.4% 19 7.2% 
Anti-inflammatory+antibiotic 50 3.2% 82 31.1% 
No drug 1130 72.8% 8 3.0% 
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within 3 days, and over 7 days were significantly differ-
ent between groups (Figure 2). In particular, 51.4% of 
Broncalt-treated patients and 42.4% of patients with-
out Broncalt treatment had no more symptoms within 
3 days (p=0.007). On the contrary, 24.5% of patients 
without Broncalt treatment and 36.4% of Broncalt-
treated patients still present symptoms over one week 
(p<0.001).
In patients treated with Broncalt, the perception 
of efficacy was very good in 77.8% and good in 19.5% 
(Figure 3A); the tolerability was very good in 87.8% 
and good in 11.9% (Figure 3B); the compliance was 
very good in 85.5% and good in 13% (Figure 3C).
The treatment was well tolerated by all patients 
and no relevant adverse event was reported.
Table 2. Proportion of patients without symptoms and signs 
after treatment in the two subgroups: treated with or without 
Broncalt, evaluated at T1
Symptom Broncalt  No Broncalt  P
Facial pain 20.2% 25.4% 0.054
Nasal Obstruction 39.9% 31.4% 0.009
Rhinorrea 40.9% 34.5% 0.049
Post nasal drip  27.71% 18.9% 0.003
Earache 16.6% 18.6% 0.435
Nose swelling 29.6% 26.9% 0.379
Sore throat 21.1% 25.4% 0.121
Dysphonia 24.9% 21.2% 0.202
Cough 33.6% 32.6% 0.741
Hyperaemia 50.1% 40.5% 0.004
Edema 24.3% 23.9% 0.885
Figure 1. Visual Analogue Scale scores at T0 and T1 in patients treated with or without Broncalt concerning facial pain, earache, 
and sore throat
G.F. Cupido, M. Gelardi, I. La Mantia, et al.34
Discussion
At present, there is great interest in the comple-
mentary medicine to improve human diseases, includ-
ing inflammatory/infectious diseases. 
Chronic inflammation entails the accumulation 
of cells and exudates in involved tissues. Inflamma-
tion has been studied since thousands of years with the 
aim of contrasting its effects on the body. In AD 30, 
Celsius described the 4 classic signs of inflammation 
(rubor, calor, dolor, and tumor) and used extracts of wil-
low leaves to relieve them. For many years, salicylate-
containing plants were applied therapeutically and 
lead to the production of a major anti-inflammatory 
Figure 2. Percentages of patients treated with or without Bron-
calt with symptom disappearance within 3 days, between 3 and 
7 days, and over 7 days
Figure 3. A= Patients’ perception of Broncalt efficacy; B= Patients’ perception of Broncalt tolerability; C= Patients’ perception of 
Broncalt Compliance
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drug (acetylsalicylate). Acetylsalicylate, an agent with 
anti-inflammatory activity, is derived from natu-
ral sources, and is used extensively in current clinical 
practice. It represents the paradigmatic example of the 
use of plant-derived compounds in medicine. Many 
other salicylate-like drugs are now available including 
the non-steroid anti-inflammatory drugs (NSAIDs). 
However, a long-lasting use of these compounds may 
commonly induce adverse events, even severe.
Natural products with anti-inflammatory activity 
have long been used as a folk remedy for inflammatory 
conditions such as fevers, pain, migraine and arthritis. 
As the inflammatory basis of disease becomes clear, 
anti-inflammatory food products become of greater 
interest. In this regard, the medical device Broncalt® 
contains extracts of grapefruit, HA, and thermal water 
of Medesano.
Currently, the mechanisms of action of these 
molecules have been identified and examined in depth, 
thus, their clinical use is no longer empirical but based 
also on solid scientific grounds. In particular, Bron-
calt® may exert a relevant anti-inflammatory-antimi-
crobial activity.
The current survey demonstrated that Broncalt® 
significantly improved the clinical feature in chronic 
respiratory ORL disorders in clinical practice. Inter-
estingly, the effectiveness was quick as many symptoms 
disappeared in Broncalt-treated patients within 3 days. 
Moreover, it has to be noted that most of Broncalt-
treated patients did not take any other medication, and 
in any case took less antibiotics and anti-inflammatory 
drugs.
The present findings are consistent with a previ-
ous study that explored the therapeutic effects of simi-
lar multi-component nutraceuticals in the treatment of 
chronic ORL diseases (6). 
Therefore, the present survey confirms that Bron-
calt® was able to significantly reduce clinical features 
in patients with chronic ORL disorders characterized 
by an inflammatory reaction. However, the current ex-
perience has some limitations, mainly concerning the 
open design and the lack of objective functional data. 
On the other hand, the strength of this survey is the 
high number of enrolled patients and the real-world 
setting, so the findings may mirror what occurs in the 
daily practice.
In conclusion, the present survey evidenced that 
Broncalt® may induce a safe and quick control of res-
piratory complaints in chronic ORL disorders.
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